tiprankstipranks
Trending News
More News >
Biotest AG (DE:BIO)
HAMBURG:BIO

Biotest (BIO) AI Stock Analysis

Compare
4 Followers

Top Page

DE

Biotest

(Hamburg:BIO)

Rating:50Neutral
Price Target:
€40.00
▲(0.00%Upside)
Biotest's overall stock score is impacted primarily by its financial performance and technical analysis. While the balance sheet and cash flow improvements are positives, the technical indicators show bearish momentum, and the valuation is challenged by a negative P/E ratio. The lack of earnings call data and corporate events further limits a comprehensive assessment.

Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)

Biotest Business Overview & Revenue Model

Company DescriptionBiotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
How the Company Makes MoneyBiotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.

Biotest Financial Statement Overview

Summary
Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.
Income Statement
65
Positive
Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.
Balance Sheet
72
Positive
The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.
Cash Flow
70
Positive
Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
726.20M684.60M516.10M515.60M484.20M
Gross Profit
223.80M280.30M124.90M80.70M130.10M
EBIT
94.50M143.50M-13.00M-52.10M-13.20M
EBITDA
120.40M179.00M28.30M-17.70M16.00M
Net Income Common Stockholders
26.40M127.00M-31.60M-63.30M-31.40M
Balance SheetCash, Cash Equivalents and Short-Term Investments
119.50M118.50M136.60M117.50M89.20M
Total Assets
1.43B1.41B1.20B1.10B1.13B
Total Debt
597.20M689.80M574.30M496.30M469.10M
Net Debt
489.40M581.70M457.70M391.90M397.80M
Total Liabilities
903.30M912.00M831.90M723.80M689.70M
Stockholders Equity
530.70M498.90M371.10M380.40M441.60M
Cash FlowFree Cash Flow
32.20M-36.10M-69.80M15.70M-43.70M
Operating Cash Flow
60.90M-2.70M-40.50M33.90M-16.70M
Investing Cash Flow
-25.70M1.30M-37.00M-23.40M-14.60M
Financing Cash Flow
-35.40M-6.80M89.60M22.60M42.00M

Biotest Technical Analysis

Technical Analysis Sentiment
Negative
Last Price40.00
Price Trends
50DMA
42.47
Negative
100DMA
41.77
Negative
200DMA
41.68
Negative
Market Momentum
MACD
-0.35
Positive
RSI
21.26
Positive
STOCH
6.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Negative. The current price of 40 is below the 20-day moving average (MA) of 42.47, below the 50-day MA of 42.47, and below the 200-day MA of 41.68, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 21.26 is Positive, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO.

Biotest Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
DEBIO
50
Neutral
€1.40B64.15-4.72%0.16%-18.82%-113.85%
€1.38B40.4217.48%3.05%
€771.72K
€1.27B-20.51%
$354.31M21.812.99%
DEFYB
63
Neutral
€504.32M5.89-26.06%-10.32%-250.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BIO
Biotest
40.00
-1.00
-2.44%
GB:0NZY
Eckert & Ziegler Strahlen und Medizintechnik
66.86
26.08
63.95%
GB:0QXH
Epigenomics
1.02
-2.78
-73.16%
GB:0IRF
Evotec
7.63
-1.02
-11.79%
MEDOF
Medios AG
13.78
-3.74
-21.35%
DE:FYB
Formycon AG
28.20
-20.20
-41.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.